Valmark Advisers Inc. Purchases 2,363 Shares of Quanterix Co. (NASDAQ:QTRX)

Valmark Advisers Inc. boosted its position in shares of Quanterix Co. (NASDAQ:QTRXFree Report) by 3.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 69,736 shares of the company’s stock after acquiring an additional 2,363 shares during the period. Valmark Advisers Inc.’s holdings in Quanterix were worth $1,907,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the stock. SG Americas Securities LLC boosted its holdings in shares of Quanterix by 150.2% in the 3rd quarter. SG Americas Securities LLC now owns 14,235 shares of the company’s stock worth $386,000 after acquiring an additional 8,546 shares in the last quarter. Robeco Institutional Asset Management B.V. acquired a new position in shares of Quanterix in the 3rd quarter worth approximately $67,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in shares of Quanterix by 56.5% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,683 shares of the company’s stock worth $209,000 after acquiring an additional 2,775 shares in the last quarter. Emerald Advisers LLC acquired a new position in Quanterix during the 3rd quarter worth $10,462,000. Finally, Emerald Mutual Fund Advisers Trust lifted its holdings in Quanterix by 353.4% during the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 313,044 shares of the company’s stock worth $8,496,000 after buying an additional 243,994 shares in the last quarter. 86.48% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Quanterix

In other news, Director Laurie J. Olson sold 1,500 shares of the stock in a transaction dated Wednesday, February 14th. The shares were sold at an average price of $24.35, for a total transaction of $36,525.00. Following the completion of the transaction, the director now directly owns 15,238 shares in the company, valued at approximately $371,045.30. The transaction was disclosed in a document filed with the SEC, which is available at this link. 6.80% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Separately, Scotiabank upped their price objective on Quanterix from $30.00 to $32.00 and gave the stock a “sector outperform” rating in a report on Monday, March 4th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Quanterix presently has a consensus rating of “Buy” and a consensus target price of $32.00.

Read Our Latest Report on QTRX

Quanterix Price Performance

Shares of Quanterix stock traded down $0.03 on Friday, hitting $15.56. 258,697 shares of the company’s stock traded hands, compared to its average volume of 361,444. The firm’s 50-day moving average price is $22.74 and its two-hundred day moving average price is $23.33. The stock has a market capitalization of $595.17 million, a PE ratio of -18.09 and a beta of 1.30. Quanterix Co. has a one year low of $11.60 and a one year high of $29.70.

Quanterix (NASDAQ:QTRXGet Free Report) last issued its earnings results on Thursday, February 29th. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.05). The business had revenue of $31.55 million for the quarter, compared to the consensus estimate of $27.92 million. Quanterix had a negative net margin of 26.42% and a negative return on equity of 9.15%. On average, analysts forecast that Quanterix Co. will post -1.04 earnings per share for the current fiscal year.

Quanterix Profile

(Free Report)

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.

See Also

Want to see what other hedge funds are holding QTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quanterix Co. (NASDAQ:QTRXFree Report).

Institutional Ownership by Quarter for Quanterix (NASDAQ:QTRX)

Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.